About Servier Symphogen
Servier Symphogen is a Healthcare company based in Ballerup (Denmark) founded in 2000, and was acquired by Servier in April 2020. Servier Symphogen is focused on developing antibody therapeutics for cancer. It operates on a Professional Services model. Servier Symphogen has raised $671.45 million across 15 funding rounds from investors including Takeda Pharmaceuticals, HHS and Genentech. The company has 103 employees. Servier Symphogen was last valued at $281.31 million in May 2019. Its chief executive is Martin Olin. Servier Symphogen offers products and services including Antibody Therapeutics. Its focus areas include Biotechnology and Oncology. Its legal entity is Servier Symphogen A/S. Its competitors include Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen and 2 more; 7 of its 7 listed competitors have raised funding.
Company details
Servier Symphogen is recognized as the Antibody Center of Excellence within the Servier Group. The company is primarily engaged in oncology and immune oncology sectors. A highly efficient antibody discovery and research platform is utilized, supported by comprehensive early development capabilities. Unique functionalities in antibodies are delivered, offering potential for best or first-in-class treatments as combination or monotherapy. Combination therapies, central to future cancer treatments, are well-suited to the companys approach and capabilities. Scientific innovation is emphasized as the core of advancing cancer therapies.
- Headquarters Ballerup, Denmark
- Employees 103
- Stage Acquired
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website symphogen.com
- Social LinkedIn X
- Acquired by Servier (Apr 2020)
- Legal Name Servier Symphogen A/S
- Annual Revenue$73.72 M (USD)308as on Sep 30, 2021
- Net Profit$13.95 M (USD)142as on Sep 30, 2021
- Total Equity Funding$671.45M (USD)
in 15 rounds
- Latest Funding Round$58.84M (USD), Series F
May 2019
- InvestorsTakeda Pharmaceuticals
& 11 more
- Employee Count103
- Acquired byServier
(Apr 2020)
Products & Services of Servier Symphogen
Servier Symphogen offers a comprehensive portfolio of products and services, including Antibody Therapeutics.
Antibody therapeutics are developed for cancer treatment solutions.
Funding Insights of Servier Symphogen
Servier Symphogen has successfully raised a total of $671.45M across 15 strategic funding rounds. The most recent funding activity was a Series F round of $58.84 million completed in May 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $671.45M
- Total Rounds 15
- Last Round Series F — $58.84M
- First Round $1.6M
(May 2000)
- Investors Count 11
Latest 10 of 15 funding rounds of Servier Symphogen with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2019 | $58.84M | Series F | $281.31M | – | – |
| Nov 2017 | $5M | Series F | – | Genentech | – |
| Oct 2015 | $76.62M | Series F | $421.64M | PKA, Novo Holdings | – |
| May 2013 | $185.8M | Series F | – | PKA, Danica Pension | – |
| Feb 2012 | $34M | Series E | $••••• | – | – |
| Jan 2011 | $134M | Series E | – | PKA | |
| Feb 2009 | $42.52M | Series E | $••••• | EW Healthcare Partners | – |
| Aug 2008 | $620,101 | Grant | – | – | |
| Jun 2008 | $37.2M | Series D | – | – | – |
| Jan 2007 | $6.47M | Series D | – | Gilde Healthcare | – |
| Date | Valuation | Stage |
|---|---|---|
| May 2019 | $281.31M | •••••••• |
| Oct 2015 | $421.64M | •••••••• |
| Feb 2012 | $••••• | •••••••• |
| Feb 2009 | $••••• | •••••••• |
| Jan 2006 | $••••• | •••••••• |
| Oct 2005 | $••••• | •••••••• |
Full valuation and stage history of Servier Symphogen
Every valuation point, the growth-stage changes (minicorn, soonicorn, unicorn) and the dates behind them require an active premium plan.
- All valuation points
- Stage changes
- Dates
- Exports
Verified entity values are shown only after access is granted.
Last known valuation $281.31M (May 2019). 12 investors in total: 12 institutional.
Investors in Servier Symphogen
Servier Symphogen has secured backing from 12 investors, including institutional and venture fund investors. Prominent investors backing the company include Takeda Pharmaceuticals, HHS and Genentech.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity and venture capital fund focused on the healthcare sector | – | novoholdings.dk | Hellerup, Denmark | |
Growth-stage healthcare companies are invested in by EW Healthcare Partners. | – | ewhealthcare.com | New York, United States | |
Private equity and venture captial firm focused on healthcare sectors | – | gildehealthcare.com | Cambridge, United States | |
Provision of financing, loans, equity, and insurance for Danish export and investment activities. | – | vf.dk | - | |
R&D company focused on manufacturing drugs for multiple therapeutic areas | 1976 | gene.com | San Francisco, United States | |
Serves as a pension fund providing benefits for employees. | 1954 | pka.dk | Hellerup, Denmark | |
Pensions are managed for Danish employees through financial investments. | 1842 | danicapension.dk | Kongens Lyngby, Denmark | |
Administers holiday and hardship funds for Danish employees and employers. | 1980 | ld.dk | Hojbjerg, Denmark | |
Takeda Pharmaceuticals is engaged in developing innovative medicines globally. | 1781 | takeda.com | Tokyo, Japan | |
Specializes in research and development of pharmaceutical drugs to advance medical solutions. | 1996 | mediconvalley.com | Denmark |
Investor details for Servier Symphogen
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Servier Symphogen
69 people are tracked at Servier Symphogen (14 in leadership, 3 in board & advisors, 52 in team); the tracked headcount is 103.
| Name | Role | Group |
|---|---|---|
Martin Olin | CEO | Leadership |
Janus Schou Jakobsen | Associate Scientific Director | Leadership |
Dan Bach Kristensen | Scientific Director | Leadership |
Christophe Thurieau | CEO | Leadership |
Søren Kofoed Rasmussen | Scientific Director | Leadership |
Ivan Horak | Chief Scientific and Medical Officer | Leadership |
Dorthe Sandager Bilde | CMC Project Director | Leadership |
Klaus Koefoed | Senior Scientific Director Antibody Technology Innovation | Leadership |
Trine Lindsted | Director, Target Biology and Assays | Leadership |
Mads Laustsen | Chief Manufacturing Officer | Leadership |
Michael Herbst | Vice President, Finance & Procurement | Leadership |
Claus Haase | Senior Vice President, Biologics Drug Design, Symphogen - A Servier Company | Leadership |
Maiken Jæger Knudsen | CMC Project Director | Leadership |
Gorm Andersen | Head Of Department | Leadership |
Pascal Lemaire | Board Member | Board & advisors |
Benoit Chéron | Board Member | Board & advisors |
Claude Bertrand | Chairman | Board & advisors |
Heidi Møller Hansen | Research Assistant | Team |
Pontip Prasomsat Isager Henriksen | Laboratory Technician | Team |
Nicoline Anesen | Laboratory Technician | Team |
49 more people are available in the full profile.
Complete people profiles for Servier Symphogen
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Servier Symphogen
5 dated milestones of Servier Symphogen across 20 years, from founding to its latest funding, stage changes and deals.
- Founded Servier Symphogen is founded.
- Funding First funding round of $1.6M.
- Milestone Reaches Minicorn status.
- Funding Latest funding round, Series F, of $58.8M.
- Exit Acquired by Servier.
Competitors of Servier Symphogen
Servier Symphogen has 7 listed competitors in our database, 7 of them funded. They include Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| jazzpharma.com | 2003 | Dublin, Ireland | $265M | 2,800 | Novel biopharmaceutical medicines are developed for unmet medical needs. | |
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. | |
| erasca.com | 2018 | San Diego, United States | $300M | 120 | Small molecule therapeutics for cancer treatment are developed. | |
| revmed.com | 2014 | Redwood, United States | $326.29M | 181 | Cancer therapies are developed using selective pathway inhibitors. | |
| miragen.com | 2007 | Boulder, United States | $111.29M | 92 | MicroRNA-based therapeutics are developed for treating multiple diseases. | |
| mereobiopharma.com | 2015 | London, United Kingdom | $119M | 56 | Therapeutics for cancer and rare diseases are developed. | |
| nimbustx.com | 2009 | Cambridge, United States | $685M | 81 | Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed. |
Detailed competitors of Servier Symphogen
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Servier Symphogen
The website of Servier Symphogen (symphogen.com) receives about 2K visits a month and ranks #10,573,730 among all websites worldwide, #7,942 in Biotechnology and Pharmaceuticals.
- Monthly visits2K
▲ 37.7% vs previous month
- Global rank#10,573,730
among all websites
- Category rank#7,942
Health · Biotechnology and Pharmaceuticals
- Bounce rate34%
- Pages per visit1.6
- Average visit20 sec
- DevicesDesktop 19% · Mobile 81%
Top companies in Oncology
10 companies that operate in the same segment as Servier Symphogen (Oncology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 | |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed. | 2002 | Saint-genis-pouilly, Ain, France | USD 56.13 M | USD 235.08 M | – | |
Developer of small molecule drugs for the treatment of cancer and inflammatory disease | 2008 | Natick, Massachusetts, United States | USD 98.4 M | USD 146.07 M | 279 | |
Small molecule therapeutics are developed for cancer and rare diseases. | 2017 | New York, New York, United States | USD 229.6 M | – | – | |
Small-molecule drugs for cancer treatment are developed via Degronimid platform. | 2016 | Cambridge, Massachusetts, United States | USD 223 M | USD 35.95 M | 110 | |
Developer of drugs based on T-Cell receptor technology for the treatment of cancer | 2008 | Abingdon, Oxfordshire, United Kingdom | USD 601.28 M | USD 400.95 M | 493 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Servier Symphogen
Complete news archive for Servier Symphogen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Servier Symphogen
Servier Symphogen was founded in 2000.
Servier Symphogen is headquartered in Ballerup, Denmark.
Martin Olin is the current CEO of Servier Symphogen.
Servier Symphogen is a funded company, having raised a total of $671.45M across 15 funding rounds to date. The company's 1st funding round was a Series D of $6.47M, raised on May 2000.
Servier Symphogen has 103 employees.
Annual revenue of Servier Symphogen is $73.72M as on Sep 30, 2021.
Servier Symphogen is recognized as the Antibody Center of Excellence within the Servier Group. The company is primarily engaged in oncology and immune oncology sectors. A highly efficient antibody discovery and research platform is utilized, supported by comprehensive early development capabilities. Unique functionalities in antibodies are delivered, offering potential for best or first-in-class treatments as combination or monotherapy. Combination therapies, central to future cancer treatments, are well-suited to the companys approach and capabilities. Scientific innovation is emphasized as the core of advancing cancer therapies.
Servier Symphogen's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
Servier Symphogen offers Antibody Therapeutics.
Servier Symphogen has 12 investors. Key investors include Takeda Pharmaceuticals, HHS, Genentech, Servier, and Danica Pension.
The valuation of Servier Symphogen is $281.31M as of May 2019.
Servier Symphogen operates through Servier Symphogen A/S.